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The drug 4-nitroquinoline 1-oxide (4NQO) is a model carcinogen that produces 
both DNA strand breaks (like ionizing radiation) and alkali-stable DNA lesions (like UV 
light.)  This drug has been known to induce cancer in many organisms.  However, its 
mechanism of action is not fully understood.  In most organisms including bacteria, fungi 
and mammals, mutants that are sensitive to UV light and γ-irradiation are also sensitive to 
4NQO.  However, D. discoideum radC mutants that were selected for sensitivity to UV 
and γ-irradiation were not also sensitive to 4NQO.  In contrast, D. discoideum mutants 
selected for sensitivity to 4NQO generally showed cross-sensitivity to UV and γ-
irradiation, but one mutant was uniquely sensitive to 4NQO.  None of the mutant genes 
have been identified, implying the existence of genes or pathways that specifically 
control the cells response to 4NQO.  Furthermore, a commonly used chemotherapeutic 
drug cisplatin operates in a similar way as 4NQO by forming bulky DNA adducts.  
Understanding how 4NQO functions in the cell may in turn facilitate the understanding 
of the chemotherapeutic drug cisplatin and thus, how to better administer 
chemotherapeutic treatment to metastatic cancer patients.   
 For my research I used a random insertional mutagenic technique (REMI) to 
identify genes responsible for 4NQO resistance in D. discoideum.  Two such mutations 
are discussed.  The study shows the feasibility of using genome-wide screens to identify 
novel genes that are associated with 4NQO resistance. 
 
 
 
 
